

PI3K Inhibitor Drug Class Market - 2024-2033

<https://marketpublishers.com/r/PCD1C13ACD2DEN.html>

Date: February 2026

Pages: 247

Price: US\$ 2,999.00 (Single User License)

ID: PCD1C13ACD2DEN

Abstracts

The PI3K Inhibitor Drug Class Market was valued at US\$ 1.45 Billion in 2024 and is anticipated to reach US\$ 2.3 Billion by 2033, at a CAGR of 0.055 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the PI3K Inhibitor Drug Class Market.

This report delivers a comprehensive overview of the PI3K Inhibitor Drug Class Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding PI3K Inhibitor Drug Class Market. The PI3K Inhibitor Drug Class Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

PI3K Inhibitor Drug Class Market Scope:

By Product

PI3K? selective inhibitors

PI3K? selective inhibitors

PI3K?/? selective inhibitors

Pan-Class I PI3K inhibitors

Dual PI3K/mTOR inhibitors

Other dual-target PI3K inhibitors

By Therapy Strategy

Monotherapy

Combination Therapy

By Route of Administration

Oral

Parenteral

By Line of Therapy

First-Line Therapy (1L)

Second-line (2L)

Third-line and later (3L+)

Maintenance / Long-term control

By Therapeutic Indication

Oncology

Hematologic Malignancies

Non-Oncology

By Biomarker Status

PIK3CA-mutated

PI3K pathway activation (signature-based)

PIK3CD / PIK3R1 variants

PTEN loss / AKT pathway altered (exploratory)

Biomarker-unselected

By Patient Demographics

Pediatric

Adult

Geriatric

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies / E-Pharmacies

Others

Key Players

Novartis AG

Gilead Sciences, Inc.

Bayer AG

F. Hoffmann-La Roche Ltd

Pfizer Inc.

AbbVie Inc.

Sanofi

Merck & Co., Inc

TG Therapeutics, Inc.

Verastem, Inc.

Major Highlights

This report delivers a comprehensive overview of the PI3K Inhibitor Drug Class Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding PI3K Inhibitor Drug Class Market. The PI3K Inhibitor Drug Class Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Precision-Oncology Pull from PIK3CA Mutation Testing
 - 3.1.1.2. Expanding Relapsed/Refractory Hematologic Cancer Pool
 - 3.1.1.3. Companion Diagnostic–Driven Prescribing Momentum
 - 3.1.2. Restraints
 - 3.1.2.1. Immune-Mediated Toxicity and Safety Black-Box Concerns
 - 3.1.2.2. Regulatory Tightening on Benefit–Risk Profiles
 - 3.1.3. Opportunity
 - 3.1.3.1. Next-Generation Isoform-Selective PI3K Innovation
 - 3.1.3.2. Combination Regimen Expansion Beyond Oncology
 - 3.1.4. Trends
 - 3.1.4.1. Shift from Pan-PI3K to Isoform-Specific Inhibitors
 - 3.1.4.2. Rising Withdrawals Reshaping Competitive Landscape
 - 3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

- 4.1. Porter's Five Force Analysis – Global PI3K Inhibitor Drug Class
- 4.2. Geopolitical & Supply Chain Exposure
 - 4.2.1. API Sourcing Concentration for PI3K Inhibitors
 - 4.2.2. Trade Policies, Export Controls, and Oncology Drug Supply Risks
- 4.3. Social & Patient-Centric Factors
 - 4.3.1. Physician Prescribing Behavior in Precision Oncology
 - 4.3.2. Brand Preference vs Therapeutic Switching Across PI3K Inhibitors
 - 4.3.3. Patient Switching Resistance Due to Toxicity Management and Monitoring Needs
 - 4.3.4. Awareness Gaps in Biomarker-Driven PI3K Therapy Selection
- 4.4. Economic Factors
 - 4.4.1. Reimbursement-Led Adoption in Public and Private Oncology Programs
 - 4.4.2. Inflationary Pressure on APIs, Complex Synthesis, and Oncology Manufacturing Inputs
 - 4.4.3. Currency Volatility Impacting Export-Oriented Targeted Oncology Drug Producers
- 4.5. Pricing Analysis
- 4.6. Regulatory Analysis
- 4.7. Go-To-Market (GTM) Strategy
- 4.8. Innovation & R&D Trends
- 4.9. Sustainability and ESG Analysis
- 4.10. Prescription Oncology Ecosystem Participants
 - 4.10.1. Branded PI3K Inhibitor Innovators
 - 4.10.2. Emerging Generic and Next-Generation PI3K Developers
 - 4.10.3. API and High-Potency Intermediate Suppliers
 - 4.10.4. Contract Manufacturing and Oncology-Focused CDMOs
 - 4.10.5. Specialty Distributors, GPOs, and Oncology Procurement Bodies
- 4.11. Buyer Decision Criteria & Adoption Drivers
 - 4.11.1. Safety Profile Differentiation and Toxicity Management Support
 - 4.11.2. Regulatory Track Record and Post-Approval Compliance History
 - 4.11.3. Pricing Predictability Under Value-Based Oncology Frameworks
 - 4.11.4. Portfolio Synergies Across Targeted and Precision Oncology Therapies
- 4.12. DMI Opinion – Strategic Outlook for the Global PI3K Inhibitor Drug Class Market

5. BY PRODUCT

- 5.1. Introduction

- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 5.1.2. Market Attractiveness Index, By Product
- 5.2. PI3K? selective inhibitors*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. PI3K? selective inhibitors
- 5.4. PI3K?? selective inhibitors
- 5.5. Pan-Class I PI3K inhibitors
- 5.6. Dual PI3K/mTOR inhibitors
- 5.7. Other dual-target PI3K inhibitors

6. BY THERAPY STRATEGY

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Strategy
 - 6.1.2. Market Attractiveness Index, By Therapy Strategy
- 6.2. Monotherapy*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Combination Therapy
 - 6.3.1. PI3K inhibitor + Endocrine therapy
 - 6.3.2. PI3K inhibitor + CDK4/6 inhibitor
 - 6.3.3. PI3K inhibitor + Anti-HER2 therapy
 - 6.3.4. PI3K inhibitor + Chemotherapy
 - 6.3.5. PI3K inhibitor + Immunotherapy
 - 6.3.6. PI3K inhibitor + Targeted therapy (non-PI3K)
 - 6.3.7. PI3K inhibitor + Anti-CD20 / chemoimmunotherapy regimens
 - 6.3.8. Other combinations

7. BY ROUTE OF ADMINISTRATION

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 7.1.2. Market Attractiveness Index, By Route of Administration
- 7.2. Oral*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Parenteral

- 7.3.1. Intravenous
- 7.3.2. Intramuscular
- 7.3.3. Subcutaneous
- 7.3.4. Intradermal

8. BY LINE OF THERAPY

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy
 - 8.1.2. Market Attractiveness Index, By Line of Therapy
- 8.2. First-Line Therapy (1L)*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Second-line (2L)
- 8.4. Third-line and later (3L+)
- 8.5. Maintenance / Long-term control

9. BY THERAPEUTIC INDICATION

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Indication
 - 9.1.2. Market Attractiveness Index, By Therapeutic Indication
- 9.2. Oncology*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 9.2.3. Solid Tumors
 - 9.2.4. Breast Cancer (HR+/HER2-, PIK3CA-mutated)
 - 9.2.5. Endometrial Cancer
 - 9.2.6. Head & Neck Squamous Cell Carcinoma
 - 9.2.7. Colorectal Cancer
 - 9.2.8. Non-Small Cell Lung Cancer
 - 9.2.9. Other solid tumors (basket / biomarker-driven)
- 9.3. Hematologic Malignancies
 - 9.3.1. Follicular Lymphoma
 - 9.3.2. Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL)
 - 9.3.3. Marginal Zone Lymphoma
 - 9.3.4. Diffuse Large B-Cell Lymphoma
 - 9.3.5. Mantle Cell Lymphoma
 - 9.3.6. Other Non-Hodgkin Lymphomas

9.3.7. Other hematologic malignancies

9.4. Non-Oncology

9.4.1. PIK3CA-Related Overgrowth Spectrum (PROS)

9.4.2. Activated PI3K? Syndrome (APDS)

9.4.3. Primary Immunodeficiency / Immune Dysregulation Disorders

9.4.4. Autoimmune Disorders

9.4.5. Inflammatory Diseases

9.4.6. Other non-oncology indications

10. BY BIOMARKER STATUS

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status

10.1.2. Market Attractiveness Index, By Biomarker Status

10.2. PIK3CA-mutated*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

10.3. PI3K pathway activation (signature-based)

10.4. PIK3CD / PIK3R1 variants

10.5. PTEN loss / AKT pathway altered (exploratory)

10.6. Biomarker-unselected

11. DIAGNOSTIC APPROACH

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach

11.1.2. Market Attractiveness Index, By Diagnostic Approach

11.2. Tissue-based testing

11.3. Liquid biopsy (ctDNA)

11.4. Clinical phenotype-based (rare disease)

12. BY PATIENT DEMOGRAPHICS

12.1. Introduction

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics

12.1.2. Market Attractiveness Index, By Patient Demographics

12.2. Pediatric*

12.2.1. Introduction

- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 12.3. Adult
- 12.4. Geriatric

13. BY DISTRIBUTION CHANNEL

- 13.1. Introduction
 - 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 13.1.2. Market Attractiveness Index, By Distribution Channel
- 13.2. Hospital Pharmacies*
 - 13.2.1. Introduction
 - 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 13.3. Retail Pharmacies
- 13.4. Online Pharmacies / E-Pharmacies
- 13.5. Others

14. BY REGION

- 14.1. Introduction
 - 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 14.1.2. Market Attractiveness Index, By Region
- 14.2. North America
 - 14.2.1. Introduction
 - 14.2.2. Key Region-Specific Dynamics
 - 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
 - 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Selectivity
 - 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy
 - 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Indication
 - 14.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status
 - 14.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach
 - 14.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics
 - 14.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 14.2.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.2.12.1. US
 - 14.2.12.2. Canada

14.2.12.3. Mexico

14.3. Europe

14.3.1. Introduction

14.3.2. Key Region-Specific Dynamics

14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Selectivity

14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy

14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Indication

14.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status

14.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach

14.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Demographics

Demographics

14.3.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14.3.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

14.3.12.1. Germany

14.3.12.2. UK

14.3.12.3. France

14.3.12.4. Russia

14.3.12.5. Italy

14.3.12.6. Spain

14.3.12.7. Norway

14.3.12.8. Netherlands

14.3.12.9. Sweden

14.3.12.10. Denmark

14.3.12.11. Belgium

14.3.12.12. Switzerland

14.3.12.13. Austria

14.3.12.14. Poland

14.3.12.15. Finland

14.3.12.16. Rest of Europe

14.4. Latin America

14.4.1. Introduction

14.4.2. Key Region-Specific Dynamics

14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Selectivity

14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy

14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic

Indication

14.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status

14.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach

14.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient

Demographics

14.4.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14.4.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

14.4.12.1. Brazil

14.4.12.2. Argentina

14.4.12.3. Rest of Latin America

14.5. Asia-Pacific

14.5.1. Introduction

14.5.2. Key Region-Specific Dynamics

14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Selectivity

14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy

14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic

Indication

14.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status

14.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach

14.5.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient

Demographics

14.5.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14.5.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

14.5.12.1. China

14.5.12.2. India

14.5.12.3. Japan

14.5.12.4. Australia

14.5.12.5. South Korea

14.5.12.6. New Zealand

14.5.12.7. Indonesia

14.5.12.8. Malaysia

14.5.12.9. Philippines

14.5.12.10. Singapore

14.5.12.11. Thailand

14.5.12.12. Vietnam

14.5.12.13. Rest of Asia-Pacific

14.6. Middle East and Africa

14.6.1. Introduction

14.6.2. Key Region-Specific Dynamics

14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Selectivity

14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Line of Therapy

14.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic

Indication

14.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Status

14.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Approach

14.6.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient

Demographics

14.6.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14.6.12. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

14.6.12.1. UAE

14.6.12.2. Saudi Arabia

14.6.12.3. South Africa

14.6.12.4. Israel

14.6.12.5. Egypt

14.6.12.6. Turkey

14.6.12.7. Qatar

14.6.12.8. Kuwait

14.6.12.9. Oman

14.6.12.10. Bahrain

14.6.12.11. Rest of Middle East and Africa

15. COMPETITIVE LANDSCAPE ANALYSIS

15.1. Competitive Scenario

15.2. Market Positioning/Share Analysis

15.3. Mergers and Acquisitions Analysis

15.4. Partner Identification Analysis

15.5. Investment & Funding Landscape

15.6. Strategic Alliances & Innovation Pipelines

16. COMPANY PROFILES

- 16.1. Novartis AG*
 - 16.1.1. Company Overview
 - 16.1.2. Product Portfolio
 - 16.1.3. Revenue Analysis
 - 16.1.4. Pricing Analysis
 - 16.1.5. SWOT Analysis
 - 16.1.6. Recent Developments
 - 16.1.6.1. Major Deals
 - 16.1.6.2. M&A
 - 16.1.6.3. Collaboration
 - 16.1.6.4. Acquisition
 - 16.1.6.5. Joint Ventures
 - 16.1.6.6. Innovations
 - 16.1.7. Recent News
 - 16.1.7.1. Events
 - 16.1.7.2. Conferences
 - 16.1.7.3. Symposiums
 - 16.1.7.4. Webinars
- 16.2. Gilead Sciences, Inc.
- 16.3. Bayer AG
- 16.4. F. Hoffmann-La Roche Ltd
- 16.5. Pfizer Inc.
- 16.6. AbbVie Inc.
- 16.7. Sanofi
- 16.8. Merck & Co., Inc
- 16.9. TG Therapeutics, Inc.
- 16.10. Verastem, Inc. (LIST NOT EXHAUSTIVE)

17. GLOBAL PI3K INHIBITOR DRUG CLASS MARKET – RESEARCH METHODOLOGY

- 17.1. Research Data
 - 17.1.1. Secondary Data
 - 17.1.2. Primary Data
 - 17.1.3. CAGR Analysis
- 17.2. Market Size Estimation Methodology

- 17.2.1. Bottom-Up Approach
- 17.2.2. Top-Down Approach
- 17.3. Market Breakdown & Data Triangulation
- 17.4. Research Assumptions
- 17.5. Limitations

18. APPENDIX

- 18.1. About Us and Services

I would like to order

Product name: PI3K Inhibitor Drug Class Market - 2024-2033

Product link: <https://marketpublishers.com/r/PCD1C13ACD2DEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PCD1C13ACD2DEN.html>